Palliative chemotherapy of head and neck cancer: Present status and future development;Palliative chemotherapie von kopf-hals-tumoren: Aktueller stand und neue entwicklungen

Laryngo- Rhino- Otologie

Volumn 85, Issue 3, 2006, Pages 172-178

  Hennemann, Burkhard ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Chemotherapy; Cisplatin; Head and neck neoplasms; Molecular therapy; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; VINCA ALKALOID;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; MONOTHERAPY; NEUTROPENIA; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; DISEASE PROGRESSION; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33645542766     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-921107     Document Type: Review

References (43)

1. Lang S, Wollenberg B, Dellian M, Steuer-Vogt MK, Schwenzer K, Sautier W, Chucholowski M, Eckel R, Faas I, Wilmes E, Ehrenfeld M, Arnold W, Kastenbauer E, Holzel D. Klinische und epidemiologische Daten zu Malignomen des Kopf-Hals-Bereichs. Larngo-Rhino-Otol 2002; 81: 499-508
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184-194
3. Kath R. Chemotherapie bei Kopf-Hals-Karzinomen. Onkologe 2001; 7: 557-562
4. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist 2000; 5: 199-208
5. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H, Kaye SB. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-547
6. Samlowski WE, Gundacker H, Kuebler JP, Giguere JK, Mills GM, Schuller DE, Ensley JF. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study. Invest New Drugs 2001; 19: 311-315
7. Testolin A, Recher G, Cristoferi V, Gasparini G. Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study. Invest New Drugs 1994; 12: 231-234
8. Degardin M, Oliveira J, Geoffrois L, Rolland F, Armand JP, Bastit P, Chauvergne J, Fargeot P, van Glabbeke M, Lentz MA, Tresca P, Boudillet J, Fumoleau P, Cappelaere P. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1998; 9: 1103-1107
9. Saxman S, Mann B, Canfield V, Loehrer P, Vokes E. A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 1998; 21: 398-400
10. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, Rozencweig M. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263
11. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, Von Hoff DD. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251
12. Kurzgefasste Interdisziplinäre Leitlinien. Deutsche Krebsgesellschaft e.V. München: W. Zuckschwerdt Verlag, 2004
13. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521-526
14. Pivot X, Chamorey E, Guardiola E, Magne N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 2003; 14: 1578-1586
15. Hitt R, Jimeno A, Rodriguez-Pinilla M, Rodriguez-Peralto JL, Millan JM, Lopez-Martin A, Brandariz A, Pena C, Cortes-Funes H. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer 2004; 91: 2005-2011
16. Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, Alafaci E, Scimone A, Spano F, Spitaleri G. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol 2004; 40: 525-531
17. Moosmann P, Egli F, Stahel RA, Jost L. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 2003; 26: 568-572
18. Fountzilas G, Athanassiades A, Kalogera-Fountzila A, Samantas E, Bacoyiannis C, Briassoulis E, Pavlidis N, Kosmidis P, Skarlos D. Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer. Semin Oncol 1997; 24: S19-S19
19. Murphy B, Li Y, Cella D. Phase III study comparing cisplatin and 5-fluorouracil versus cisplatin and paclitaxel in metastatic/recurrent head and neck cancer. Proc Am Soc Clin Oncol 2001; 20: 224 (abstract)
20. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20: 1593-1599
21. Hitt R, Castellano D, Hidalgo M, Garcia-Carbonero R, Pena M, Brandariz A, Millan JM, Alvarez Vincent JJ, Cortes-Funes H. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol 1998; 9: 1347-1349
22. Gebbia V, Mantovani G, Agostara B, Contu A, Farris A, Colucci G, Cognetti F, Restivo G, Speciale R, Ferrero B, Testa A, Curreli L, Cardinale A, Bajerta E, Gebbia N. Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial. Ann Oncol 1995; 6: 987-991
23. Gebbia V, Testa A, Di Gregorio C, Ingria F, Valenza R, Cannata G, Moschella F, Restivo G, Gebbia N. Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. Am J Clin Oncol 1995; 18: 293-296
24. Gebbia V, Mantovani G, Farris A, Agostara B, Desogus A, Curreli L, Moschella F, Di Gregorio C, Bajetta E, Gebbia N. Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study. Cancer 1997; 79: 1394-1400
25. Genet D, Cupissol D, Calais G, Bontemps P, Bourgeois H, Dutin JP, Philippi MH, Bendahmane B, Mallard-Carre M, Tubiana-Mathieu N. Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol 2004; 27: 472-476
26. Airoldi M, Cattel L, Marchionatti S, Recalenda V, Pedani F, Tagini V, Bumma C, Beatrice F, Succo G, Maria GA. Docetaxel and Vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Am J Clin Oncol 2003; 26: 378-381
27. Cupissol D, Calais G, Tourani JM, Kohser F, Borel C, Eymard JC, Dubin F, Ecstein-Fraisse E, Tubiana-Mathieu N. Phase II Study of Docetaxel plus Gemcitabine in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Proc Am Soc Clin Oncol 2003; 22: 508 (abstract)
28. Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Rev 2005; 24: 129-146
29. Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Bessa EH, Baselga J, Vermorken JB. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. J Clin Oncol 2004; 22: 5502 (abstract)
30. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587
31. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577
32. i2 Burtness B, Li Y, Flood W, Mattar BI, Forastiere AA. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 2002; 21: 226 (abstract)
33. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005; 5: 1085-1093
34. Cohen EE, Rosen F, Stadier WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987
35. Wheeler RH, Jones D, Sharma P, Davis RK, Spilker H, Boucher K, Leachman S, Grossman K, Salzman K, Akerley W. Clinical and molecular phase H study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J Clin Oncol 2005; 23: 507s (abstract)
36. Belón J, Irigoyen A, Rodríguez I, Escobar Y, Alonso J, Pastor P, Valdivia J, Concha A, Nuevo J, Bovio H. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 515s (abstract)
37. Schoffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J. Hanauske AR. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10: 119-122
38. Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000; 11: 845-849
39. Hitt R, Jimeno A, Millan JM, Castellano D, Cortes-Funes H. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer 2004; 101: 768-775
40. Schena M, Barone C, Birocco N, Dongiovanni D, Numico G, Colantonio I, Bertetto O. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study. Cancer Chemother Pharmacol 2005; 55: 271-276
41. Iop A, Cartei G, Isaia A. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil. Ann Oncol 1998; 9: 225-227
42. Fountzilas G, Stathopoulos C, Nicolaides C, Kalogera-Fountzila A, Kalofonos H, Nikolaou A, Bacoyiannis C, Samantas E, Papadimitriou C, Kosmidis P, Daniilidis J, Pavlidis N. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 475-478
43. Airoldi M, Cattel L, Cortesina G, Giordano C, Passera R, Pedani F, Novello S, Bumma C, Gabriele P. Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Anticancer Res 2003; 23: 2845-2852